JP2022520061A5 - - Google Patents
Info
- Publication number
- JP2022520061A5 JP2022520061A5 JP2021546264A JP2021546264A JP2022520061A5 JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5 JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803299P | 2019-02-08 | 2019-02-08 | |
| US62/803,299 | 2019-02-08 | ||
| PCT/US2020/017364 WO2020163823A2 (en) | 2019-02-08 | 2020-02-07 | Therapeutic agents and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520061A JP2022520061A (ja) | 2022-03-28 |
| JP2022520061A5 true JP2022520061A5 (cg-RX-API-DMAC7.html) | 2023-05-23 |
Family
ID=71948254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546264A Pending JP2022520061A (ja) | 2019-02-08 | 2020-02-07 | 治療薬および治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220169628A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3920923A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022520061A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210137025A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113660937A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020218367A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127501A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020163823A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3163593A1 (en) * | 2020-01-15 | 2021-07-22 | Guangrong Zheng | Therapeutic agents and methods of treatment |
| US12673106B2 (en) | 2020-08-28 | 2026-07-07 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的bcl-xl protac化合物及び使用の方法 |
| US20240408085A1 (en) * | 2021-09-01 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CN118660886A (zh) | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
| CA3240051A1 (en) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| CN116396288B (zh) * | 2022-01-04 | 2026-04-03 | 上海科技大学 | 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用 |
| AU2023264537A1 (en) | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| US20260092057A1 (en) * | 2022-05-12 | 2026-04-02 | Kymera Therapeutics, Inc. | Bcl-xl/bcl-2 degraders and uses thereof |
| CN115028679B (zh) * | 2022-08-11 | 2022-11-15 | 深圳湾实验室 | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 |
| CN120659777A (zh) * | 2022-10-03 | 2025-09-16 | 佛罗里达大学研究基金公司 | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| CN120569222A (zh) * | 2023-01-18 | 2025-08-29 | 苏州宜联生物医药有限公司 | 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途 |
| CN121652220A (zh) * | 2023-02-17 | 2026-03-13 | 正大天晴药业集团股份有限公司 | 含有三氟甲磺酰基的化合物 |
| AU2024378690A1 (en) | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL327973A (en) | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| KR20260111020A (ko) | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| WO2026015489A1 (en) * | 2024-07-08 | 2026-01-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CN109152933B (zh) * | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| US20240398764A1 (en) * | 2021-10-12 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| CN118660886A (zh) * | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
-
2020
- 2020-02-07 WO PCT/US2020/017364 patent/WO2020163823A2/en not_active Ceased
- 2020-02-07 AU AU2020218367A patent/AU2020218367A1/en not_active Abandoned
- 2020-02-07 KR KR1020217028572A patent/KR20210137025A/ko not_active Ceased
- 2020-02-07 CN CN202080027337.5A patent/CN113660937A/zh active Pending
- 2020-02-07 JP JP2021546264A patent/JP2022520061A/ja active Pending
- 2020-02-07 EP EP20753239.1A patent/EP3920923A4/en not_active Withdrawn
- 2020-02-07 CA CA3127501A patent/CA3127501A1/en active Pending
- 2020-02-07 US US17/429,207 patent/US20220169628A1/en active Pending